[{"orgOrder":0,"company":"NEC OncoImmunity","sponsor":"Vaximm AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Acquisition","leadProduct":"Necvax Neo 1","moa":"Cytotoxic T-Cell","graph1":"Oncology","graph2":"Preclinical","graph3":"NEC OncoImmunity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NEC OncoImmunity \/ NEC OncoImmunity","highestDevelopmentStatusID":"4","companyTruncated":"NEC OncoImmunity \/ NEC OncoImmunity"}]

Find Clinical Drug Pipeline Developments & Deals by NEC OncoImmunity

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          American Pharma Summit
                          Not Confirmed
                          American Pharma Summit
                          Not Confirmed

                          Details : Under the agreement, NOI will acquire VAXIMM’s neoantigen vaccine-related patents including VXM01, which is being developed for the treatment of glioblastoma, license the requisite manufacturing patents, and will take over existing contracts with colla...

                          Brand Name : Necvax Neo 1

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          March 08, 2022

                          Lead Product(s) : Necvax Neo 1

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Vaximm AG

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank